The ADHD-Autism Connection: A Step Toward More Accurate Diagnosis and Effective Treatments

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: I read with interest the letter to the editor by Dr. Ahmed and colleagues at the Lilly Research Laboratories in Indianapolis, Indiana, regarding our article¹ in the last issue of the journal. I agree with the authors that olanzapine has the best available data for efficacy in bipolar disorder, which is the reason, as they point out, that it has approval from the U.S. Food and Drug Administration(FDA) for the treatment of acute mania. However, the authors are incorrect in stating that there is no clinical trial demonstrating risperidone’s efficacy as a monotherapeutic agent in bipolar disorder.